Aastrom Biosciences, Inc. Says FDA Lifts Clinical Hold from Heart Study
Reuters -- Aastrom Biosciences Inc said U.S. health regulators removed the clinical hold from the company's mid-stage trial of a treatment for congestive heart failure, sending its shares up 39 percent in premarket trade.